USA flag logo/image

An Official Website of the United States Government

Tenascin-C-Fragments for Spinal Cord Regeneration

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
54644
Program Year/Program:
2001 / SBIR
Agency Tracking Number:
1R43NS041685-01
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Acorda Therapeutics, Inc.
15 Skyline Drive Hawthorne, NY 10532
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2001
Title: Tenascin-C-Fragments for Spinal Cord Regeneration
Agency: HHS
Contract: N/A
Award Amount: $100,000.00
 

Abstract:

The goal of this project is to conduct pre-clinical tests of components of the extracellular matrix molecule tenascin-C that offer potential as therapeutics for enhancing nerve fiber regeneration. This may lead to the development of a treatment for spinal cord injury, a devastating condition for which there are no reparative treatments available. The study is based on a new understanding of how the fhA-D component of tenascinC regulates neurite outgrowth. The project will examine effects of delivering fnA-D recombinant protein, or its active peptide sequence (VFDNFVLK ) to the site of an experimental spinal cord injury. Hemisection of the dorsal thoracic (T9) spinal cord of rats will be used to examine the response of corticospinal and primary afferent nerve fibers to transection and treatment with the protein and peptide. Groups of animals will be assigned to treatment with fnA-D, VFDNFVLK, or buffer delivered intrathecally for two weeks from an implanted osmotic pump. Hind limb function will be monitored with a grid-walking test. The primary measure of treatment effect will be immunohistological analysis of axonal regeneration, using Cholera toxin injected either into the motor cortex or into the sciatic nerves. Effects on regeneration of axons will be examined qualitatively and measured quantitatively. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

Principal Investigator:

Andrew R. Blight

Business Contact:


9143474300
RCOHEN@ACORDA.COM
Small Business Information at Submission:

ACORDA THERAPEUTICS
15 SKYLINE DR HAWTHORNE, NY 10532

EIN/Tax ID: 133831168
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No